Effect of Cenicriviroc on HIV Neurocognitive Impairment

Inclusion Criteria: * 4.2.1.1 Documentation of HIV-1 infection by an FDA approved test at any time prior to study entry * On ARV medication uninterrupted for \> 1 year leading up to the screening period * Screening plasma HIV RNA \< 50 copies/ml within 3 months of entry * Willingness for males and females of childbearing potential to utilize 2 effective contraception methods (2 separate forms, one of which must be an effective barrier method), be non-heterosexually active or have a an exclusive vasectomized partner from screening throughout the duration of the study treatment and for 30 days following the last dose of study drugs. * Age 18 to 70 years * Ability and willingness to provide written informed consent * Mild to moderate cognitive impairment with global neuropsychological (NP) test (NPZglobal) score of \< -0.5 or a neurocognitive abnormality (\<-0.5) in at least one cognitive domain known to be typically affected by HIV OR unimpaired * On antiretroviral (ARV) therapy consisting of nucleoside reverse transcriptase inhibitors, atazanavir with/or without ritonavir, darunavir plus ritonavir, dolutegravir, raltegravir or efavirenz. Exclusion Criteria: * Receiving or used a CCR5 antagonist within 6 months of study entry * Plasma HIV RNA \> 100 copies/ml within 6 mo. of screening * HIV-2 * Chronic hepatitis B (positive hepatitis B surface antigen) * Chronic hepatitis C (positive hepatitis C antibody), except with proof of viral clearance and normal liver function tests …